Nykode Therapeutics ASA

Nykode Therapeutics ASA, originally founded as Vaccibody AS in November 2006, is a clinical-stage biopharmaceutical company headquartered in Oslo, Norway. The company is built on technology conceived and developed at the University of Oslo and Oslo University Hospital in the laboratory of Professor Bjarne Bogen, with contributions from Professor Inger Sandlie. Its core innovation is the Vaccibody™ molecule, a modular immunotherapy platform that targets antigens to Antigen Presenting Cells (APCs) to induce fast, strong, long-lasting and broad antibody and T cell responses. The company's pipeline is focused on therapeutic cancer vaccines and immunotherapies, with a lead wholly owned candidate, Abi-suva (formerly VB10.16), an off-the-shelf therapeutic cancer immunotherapy in development for HPV16-positive cancers. Another key asset, VB10.NEO, is a proprietary individualized neoantigen immunotherapy that has been investigated in two trials across more than ten indications. Nykode also pursues applications in autoimmune diseases and infectious diseases. Nykode Therapeutics is listed on the Oslo Stock Exchange under the ticker NYKD, having uplisted to the main list. It collaborates with world-class organizations including Roche in oncology and Regeneron in a multi-target collaboration spanning oncology and infectious diseases. The company describes itself as driven to create positive change and reduce the impact of disease on people's lives, with a vision to lead the field of modular immunotherapy.

Nykode Therapeutics was founded in November 2006 under the name Vaccibody AS. The company is based on technology conceived and developed at the University of Oslo and Oslo University Hospital in the laboratory of Professor Bjarne Bogen, with contributions from Professor Inger Sandlie. The core of this technology is the Vaccibody™ molecule, a modular platform designed to target antigens to Antigen Presenting Cells to generate fast, strong, long-lasting and broad antibody and T cell responses. In December 2014, the platform patent was granted by the European Patent Office, followed by a U.S. patent grant in January 2015. In September 2015, the first patient was vaccinated in a Phase I/IIa study with VB10.16 immunotherapy for patients with HPV16-induced high-grade lesions of the cervix. In August 2016, positive results were reported from the Phase I portion of the VB C-01 trial in patients with high-grade cervical dysplasia, and the trial continued to the expansion Phase (IIa). In December 2016, the company completed a successful private placement of NOK 220 million. In June 2017, positive results from the Phase I portion of the VB C-01 trial were reported. Over the following years, the company advanced its pipeline, including its lead candidate Abi-suva (formerly VB10.16) for HPV16-positive cancers and VB10.NEO, a proprietary individualized neoantigen immunotherapy investigated in two trials across more than ten indications. The company also expanded into autoimmune and infectious disease applications. It established partnerships with Roche in oncology and a multi-target collaboration with Regeneron spanning oncology and infectious diseases. The company uplisted to the main list of the Oslo Stock Exchange, where it trades under the ticker NYKD. It rebranded from Vaccibody AS to Nykode Therapeutics, reflecting its broadened platform vision.

• 2017

  Positive results from Phase I of VB C-01 trial, a first human dose, open-label, multicenter Phase I/IIa study of VB10.16 immunotherapy for high-grade Cervical Intraepithelial Neoplasia.

• 2016

  Positive results from Phase I of VB C-01 trial in patients with high-grade cervical dysplasia; trial continued to expansion Phase (IIa).

• 2016

  Successful private placement of NOK 220 million.

• 2015

  Platform patent granted by the U.S. Patent Office.

• 2015

  First patient vaccinated in Phase I/IIa study with VB10.16 immunotherapy for HPV16-induced high-grade cervical lesions.

• 2014

  Platform patent granted by the European Patent Office.

• 2006

  Company founded under the name Vaccibody AS.

A clinical-stage biopharmaceutical platform company developing modular immunotherapies with tailored hyper-targeting to treat cancers and autoimmune diseases with high unmet medical need.

• Abi-suva (formerly VB10.16)

  A potentially first-in-class off-the-shelf therapeutic cancer immunotherapy candidate in development for HPV16-positive cancers.

• VB10.NEO

  A proprietary individualized neoantigen immunotherapy investigated in two trials across more than ten indications.

• Vaccibody™ technology platform

  A modular immunotherapy platform targeting antigens to Antigen Presenting Cells to induce fast, strong, long-lasting and broad immune responses.

1. 1Home - Nykodenykode.com
2. 2Our history - learn about Nykodenykode.com
3. 3Company profile - Nykodenykode.com
4. 4About us - Nykodenykode.com
5. 5Vaccibody AS - Wikidatawikidata.org